Immune Tolerance Network   A clinical research consortium sponsored by NIAID and JDRF
START logoA clinical research study of thymoglobulin to arrest type 1 diabetes


 

Recently diagnosed with type 1 diabetes?

Finding out that you or a family member has type 1 diabetes can be a difficult time, full of doubts and uncertainty of what lies ahead. Learning about diabetes and the choices you have for its treatment can help you with the difficult decisions you face. This site aims to introduce you to one of these options: participating in a clinical research study for new onset type 1 diabetes, called the START trial.

Type 1 diabetes is a disease in which the body’s immune system mistakenly attacks the cells that make insulin (called ‘beta cells’). Without insulin, the body cannot maintain normal blood sugar (blood glucose) levels. The result is usually a lifetime of insulin therapy, lifestyle changes and the risk of numerous long term complications from diabetes.

However, there is some good news. Generally, at the time someone is diagnosed with type 1 diabetes, not all of a person’s beta cells have been destroyed - between 15-40% remain healthy and can still make insulin. Importantly, even small amounts of naturally produced insulin can improve blood sugar control, make daily management of diabetes easier, and reduce the risk of long-term complications. Preserving these remaining precious beta cells is therefore the goal of the START trial.

Next: Learn about the START trial.

 

Recruitment is now closed.

For information on additional ITN trials for people recently diagnosed with type 1 diabetes, please visit:

Retain Study
www.retainstudy.org

T1DAL Study
www.t1dal.org

spacer Downloads

START Brochure (871 kb)

FAQ (438 kb)

Physician Reference Card (154 kb)

spacer
spacer
 
Terms of Use | Privacy | Accessibility
©2007, Immune Tolerance Network
spacer